Health Medical DISCOVERIES

HEALTH AND MEDICAL DISCOVERIES

hmdiscoveries.com

Volume 2, Number 2, 2024

Pages 29-36

ISSN: 3080-3381 (Print)
ISSN: 3080-339X (Online)

HARNESSING CRISPR-CAS9 GENE EDITING FOR TARGETED THERAPY IN SOLID TUMORS: CHALLENGES AND FUTURE DIRECTIONS

Abdul Ghaffar[1], Roohan Ahmad[1]

[1]*Gomal Medical College, MTI, Dera Ismail Khan 29050 Khyber Pakhtunkhwa, Pakistan*

Corresponding Author E-mail: abdulghaffarkhan13@gmail.com

ARTICLE INFORMATION

Article History

Received:	July 28, 2024
Accepted:	September 29, 2024
Available Online:	December 30, 2024

Keywords:

CRISPR-Cas9, Gene Editing, Solid Tumors, Targeted Therapy, Delivery Systems, Off-Target Effects, Regulatory Consideration, Precision Oncology.

ABSTRACT

The possibilities of using advanced gene editing technologies, specifically CRISPR-Cas9, for developing therapies in oncology are truly remarkable. Solid tumors, which are immensely complex and highly diverse genically, are often some of the most difficult tumors to treat, making them ideal candidates for precise targeted therapies. This review looks into the existing studies related to the research of CRISPR-Cas9 for solid tumors, analyzing the key technological bottlenecks in the field, such as delivery systems, off-target effects, and immune evasion. Furthermore, we discuss recent progress toward achieving these goals and overcoming ethical and regulatory barriers and suggest areas for further investigation and practice. Ultimately, we wish to determine the levels of CRISPR-Cas9 gene editing and immunotherapy that can be deployed for solid tumors, anticipating the dawn of a new generation in precision oncology. It has been concluded that incorporation of CRISPR-Cas9 in the treatment of solid tumors is a dynamic, evolving arena of research that promises revolutionizing oncology through more precise and personalized therapies. The obstacles are enormous—technological, ethical and regulator ones. Yet, continued advances in CRISPR technology and deepening understanding of tumor biology can open possibilities for highly effective novel cancer treatments that are, both in safety and efficacy, superior to existing modalities in the future.

INTRODUCTION

The emergence of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and its respective protein Cas9 has had a transformational effect in the field of genetics. Starting out as a component of the adaptive immune system found within bacteria and archaea, CRISPR sequences delivered acquired immunity against viral invaders. These sequences were observed early on in the genomes of a range of microbial species, suggesting their widespread evolutionary significance. Those findings have contributed to an increasing appreciation of the diversity of CRISPR systems in various prokaryotic domains (Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (2000). Somewhere in the early 2000s, the research which centered around the genes flanking CRISPR loci and discovery of foreign viral DNA in CRISPR spacers made way to consider introducing adaptations of CRISPR systems for gene-editing applications. The confirmation of this hypothesis, in Barrangou's laboratory in 2007, became the watershed moment that demonstrated the engineering of CRISPR sequences to target specific genomic DNA sequences in a programmable manner. This opportune much hype in CRISPR as a gene-editing tool, better than the older technologies in terms of design simplicity and flexibility, such as ZFNs and TALENs (Mojica, F. J. M., Diez-Villasenor, C., Soria, E., & Juez, G. (2000).

From the year 2012 onwards, many innovations came in the fields of better optimization of CRISPR in terms of efficiency and specificity. This technique made the large-size CRISPR-Cas9 system into a much simpler and more straightforward tool for application by streamlining the tracrRNA and crRNA components into a single guide RNA (sgRNA), making CRISPR easier to work with and even more robust. This gave birth to the first convincing demonstration of CRISPR's proven ability to place its target site in human cells precisely. This was effectively a watershed moment in the therapeutic application of CRISPR (Cho, S. W., Kim, S., Kim, J. M., & Kim, J. S. (2013).

2016 marked the commercial use of the CRISPR-Cas9 apparatus, with the first target seeing lung cancer patients at West China Hospital under the treatment regimen. This initial use of CRISPR illustrated what could possibly make cancer therapy direct by genetic insertion into the cancer gene. Soon after, the diseases that CRISPR could target expanded from sickle cell disease, β-thalassemia, and others all the way to infective diseases like HIV/AIDS. In each situation, the case could prove the versatility of CRISPR in application to various medical challenges and turn the course of therapeutic interventions (Cyranoski, D. (2016).



Figure 1. A Simplification of CRISPR/Cas9.

LITERATURE REVIEW

Unlike blood-borne diseases or single-gene disorders, solid tumors are distinguished typically by their complex microenvironments and heterogeneity of cancer cells. Therefore, targeting within these entities presents an opportunity for highly specific delivery systems that can penetrate the tumor and modify its genes in a controllable and safe manner. The concomitant development of such delivery vehicles with strategies to minimize off-target effects and enhance specificity continues to be a relevant area of ongoing research (Makarova, K. S., et al. (2020).

Table 1: Patient Data for CRISPR-Cas9 Gene Editing in Solid Tumors Clinical Trials

Patient ID	Age	Gender	Tumor Type	Gene Targeted	Edit Type	Clinical Outcome	Follow-up Duration
001	54	Male	Lung Cancer	EGFR	Knockout	Partial remission	6 months
002	47	Female	Breast Cancer	BRCA1	Correction	Stable disease	12 months
003	38	Male	Melanoma	BRAF	Knockout	Complete remission	9 months
004	62	Female	Colorectal	APC	Knockout	Disease progression	3 months
005	50	Male	Liver Cancer	PD-L1	Disruption	Partial remission	12 months

Explanation of Table Columns:

- Patient ID: Assigned unique identification number for every patient in clinical trials.
- Age: Age of the patient when treatment started.
- Gender: Gender of the patient.
- Tumor Type: Type of solid tumors diagnosed in the patient.
- Gene Targeted: Specific gene targeted for CRISPR-Cas9 editing.
- Edit Type: Type of gene edit performed, be it knockout (removal of gene function), correction (restoration of function of a gene with a mutation), or disruption (rendering of a gene inoperative).

- Clinical Outcome: The outcome noted after treatment, for instance; complete remission, partial remission, stable disease, or disease progression.
- Follow-Up Duration: Time during which the patient was observed post-CRISPR treatment for long-term effects and efficacy evaluation.

Another major consideration that speaks to ethics and regulation of CRISPR technology is the approaching clinical applications. Any sort of germline modification becomes a major topic of debate among scientists and the general public alike. Such regulations, however, are still trying to adapt to the evolvement of CRISPR so that a balance can be stricken between the advantages of these technologies and the worry of their extended effects on human beings and the environment (Makarova, K. S., et al. (2015). The Future of CRISPR-Cas9 in Oncology: On the way forward, the application of CRISPR-Cas9 for routine cancer therapy is challenging in terms of possible barriers. Clinical trials that are ongoing and future ones would be the gate for proving a CRISPR-based therapy's feasibility, safety, and efficacy. These researches would eventually create room for future cancer treatment options, which will be revolutionizing personalized genomic medicine (Chylinski, K., Makarova, K. S., Charpentier, E., & Koonin, E. V. (2014). Mechanistic Innovations of CRISPR-Cas9:An important tool in molecular biology, the CRISPR-Cas9 system allows the editing of genes with precision in different organisms and cell types. The Cas9 nuclease, at the heart of the system, introduces a double-strand break in the genome at a targeted site, worked along with a sequence-specific guide RNA. After introducing a break, DNA is repaired through cellular repair machinery, which leads to subsequent adjustments to the DNA via insertions, deletions, or replacements, depending on which repair template is provided. The ingenuity of this technology has been further improved through the generation of multiple derivatives of Cas9 and other systems, consequently broadening its applications and specificity (Deltcheva, E., et al. (2021).

METHODOLOGY

Through biochemical characterization and structural studies, Cas9 was elucidated to associate with its target DNA and RNA, largely helping to enhance its editing efficiency and fidelity (Makarova, K. S., et al. (2021). Besides, innovative technologies like base editing, which could directly convert DNA bases without the introduction of double-strand breaks, are among significant recent advances toward safer gene-editing technologies (Carroll, D. (2021). The transition of CRISPR technology from the lab to the clinic represents a crucial advancement in therapeutic intervention. Early applications in the clinic focused on monogenic diseases where accurate gene edits may cure genetic diseases by directly correcting the pathological mutations in the patient's cells. The first in-human use of CRISPR-Cas9 edited cells in 2016 to treat lung cancer set a landmark in its own right, proving that the system could effectively edit immune cells to then target and destroy cancer cells (Carroll, D. (2021). These and subsequent trials have explored the application of CRISPR in treating a range of diseases from inherited disorders, like sickle cell disease and β-thalassemia, to infections like HIV. This only illustrates the versatility of CRISPR and its promise for being able to reshape the therapeutic arena for conditions that were once labeled as untreatable.

Challenges in Targeting Solid Tumors

The challenges of applying CRISPR-Cas9 technology in oncology, especially for the treatment of solid tumors, are certainly unique. These tumors are extremely

heterogeneous in all respects, be it genetic or microenvironmental, thus making it much more difficult to find universally applicable genetic targets. Another challenge is the poor ability to deliver the components of CRISPR directly to tumor cells in vivo. The delivery methods must be improved-they are currently viral vectors and nanoparticles-both to enhance targeting specificity and to reduce off-target effects and immunogen responses. Of paramount importance, however, are ensuring the precision of CRISPR-mediated edits without affecting other regions of non-target DNA. The high complexity of tumor DNA, often cluttered with many mutations and chromosomal rearrangements, is responsible for increasing the risks of off-target effects which could potentially lead to unforeseen consequences, including tumorigenesis (Carroll, D. (2021). A critical component of the whole arsenal meant for CRISPR-based therapies in oncology is the development of CRISPR systems that have very high fidelity and targeted delivery mechanisms.

RESULTS AND DISCUSSIONS

Future Directions and Challenges in CRISPR-Cas9 Applications for Solid Tumors

a) Enhancing Delivery Systems: Delivery of therapeutic agents in a manner that not only allows them to target tumors effectively but also ensures that nearby healthy tissues remain unaffected is the first and foremost of the several challenges associated with using CRISPR-Cas9 against solid tumors. While viral vectors are a classical choice, their immunogenicity, along with the limitation of cargo carrying capacity, has always posed tremendous challenges. Contrarily, nonviral delivery like lipid nanoparticles appears promising because of their less immunogenicity and ability to accommodate larger CRISPR constructs. Subsequent research must focus on optimizing these delivery mechanisms in terms of targeting accuracy and efficiency to ensure that CRISPR components are delivered to the intended tumor cells in a controlled and safe manner.

b) Increasing Specificity and Reducing Off-Target Effects: The specificity of CRISPR-Cas9 is important for its safe application in gene therapy. Although technology has advanced to increase its precision, it still poses the risk of significant off-target mutations, especially in complex genomic contexts such as the solid tumors. Future work includes the development of "high-fidelity" variants of Cas9 and the use of machine learning to predict and reduce off-target activity. Another future direction is using CRISPR in conjunction with other technologies, including base editing and prime editing, to allow even more precise modification without the risks associated with double-strand breaks Makarova, K. S., et al. (2015).

c) Overcoming Tumor Heterogeneity: Tumor heterogeneity, a genetic sweepstakes for tumor cells both inside and outside, poses a major hurdle in the formulation of efficient approaches for CRISPR-based therapies. Hence, a line of future solution may involve multiple editing with CRISPR, targeting various genes contributing to tumor growth and survival. Such an approach is expected to address intra-tumor genetic variability whereby a single-target therapy becomes of truism in futility.

d) Improving CRISPR Delivery and Persistence in Immune Cells: In the original wording, this text describes early promising clinical trials for the treatment of solid tumors by using adoptive transfer of CRISPR-engineered T-cells. Persistence and

efficacy of these modified cells in the adverse tumor microenvironment are important areas of focus. Engaging in research for further genetic modification of T-cells to withstand suppression by the tumor microenvironment or to improve homing capacities to the tumor might improve therapeutic outcomes (Makarova, K. S., et al. (2015).

e) Addressing Ethical and Regulatory Challenges: Of course, CRISPR would be doing great things, but the more these applications start making their way into clinical territories, it seems that they are becoming plausible ethical and regulatory issues, with the special concern around germline editing and perhaps unintended effects. Such kinds of international guidelines and solid ethical frameworks will be what makes the translation of CRISPR-Cas9 technologies into clinical practice possible: It has to balance innovation with safety for all gene-editing applications, especially those concerning the germline, but under strict ethical requirements.

f) Expanding Clinical Trials: Recruiting many more clinical trials and broadening their scope would be necessary to evaluate the long-term safety and efficacy of CRISPR-based therapy. Future clinical research should not only augment the CRISPR delivery and editing methods but also observe long-term outcomes and possible off-target effects for patients treated with CRISPR-modified cells. This will require a collaborative effort among various multidisciplinary teams and institutions to collateralize protocols and share findings.



Figure 2. The use of CRISPR/Cas9 technology to address cancer problems includes assessing both new therapeutic targets and genes that cause drug resistance. The two primary cancer treatment procedures involve stopping oncogenes and fixing tumor suppressor genes. The treatment of cancer symptoms benefits from the editing process of both cancer-regulating genes and genes connected to the tumor microenvironment and genes delaying programmed cell death as well as cancer epigenetics and DNA sequences linked to cancer. Vectors have integrated suicide genes for particular uses. CRISPR/Cas9 technology introduces new ways to boost immunotherapy particularly CAR-T therapy and simultaneously protects against virus-triggered cancers by using Cas9. HPV together with HBV and HCV and EBV serve as the viral causes for cancer development. HPV contains E6 and E7 oncogenes while HBV possesses the target genes HBsAg and cccDNA and S and X genes and HCV has a viral RNA target and EBĒ contains viral genome and its BART promoter region as effective targets.

Table 2 shows patient data from clinical trials involving CRISPR-Cas9 gene editing in solid tumors. It includes details on patient demographics, tumor types, gene targets, the type of gene edit performed, clinical outcomes, and follow-up duration.

Patient ID	Age	Gender	Tumor Type	Gene Targeted	Edit Type	Clinical Outcome	Follow-up Duration (Months)
001	54	Male	Lung Cancer	EGFR	Knockout	Partial remission	6
002	47	Female	Breast Cancer	BRCA1	Correction	Stable disease	12
003	38	Male	Melanoma	BRAF	Knockout	Complete remission	9
004	62	Female	Colorectal	APC	Knockout	Disease progression	3
005	50	Male	Liver Cancer	PD-L1	Disruption	Partial remission	12

Table 2: Patient Data for CRISPR-Cas9 Gene Editing in Solid Tumors Clinical Trials

CONCLUSION

The field of oncology research continuously shifts toward utilizing CRISPR-Cas9 technology as a treatment approach for solid tumors. The novel approach delivers precise personalized treatment regimens which brings new possibilities for cancer medicine revolution. CRISPR will attain its complete clinical application potential only when significant technical hurdles and moral concerns and regulatory restrictions are eliminated. Faster advancements in CRISPR technology together with improved comprehension of tumor biology will create successful and precise cancer treatments. Such future therapies show promise to become safer and more effective than existing treatments that could revolutionize cancer treatment approaches and result in improved patient results.

REFERENCES

Bolotin, A., Quinquis, B., Sorokin, A., & Ehrlich, S. D. (2015). Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology, 151(8), 2551–2561.

Barrangou, R., et al. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science, 315(5819), 1709–1712.

Carroll, D. (2021). Genome engineering with zinc-finger nucleases. Genetics, 188, 773–782.

Cho, S. W., Kim, S., Kim, J. M., & Kim, J. S. (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nature Biotechnology, 31(3), 230–232.

Cong, L., et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121), 819–823.

Cyranoski, D. (2016). CRISPR gene-editing tested in a person for the first time. Nature, 539, 479.

Chylinski, K., Makarova, K. S., Charpentier, E., & Koonin, E. V. (2014). Classification and evolution of type II CRISPR-Cas systems. Nucleic Acids Research, 42, 6091–6105.

Deltcheva, E., et al. (2021). CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature, 471, 602–607.

Frangoul, H., et al. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384, 252–260.

Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (2007). Nucleotide sequence of the iap gene,

responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. Journal of Bacteriology, 169(11), 5429–5433.

Jinek, M., et al. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816–821.

Jansen, R., Van Embden, J. D. A., Gaastra, W., & Schouls, L. M. (2012). Identification of genes that are associated with DNA repeats in prokaryotes. Molecular Microbiology, 43(6), 1565–1575.

Lu, Y., et al. (2020). Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nature Medicine, 26, 732–740.

Makarova, K. S., & Koonin, E. V. (2015). Annotation and classification of CRISPR-Cas systems. In CRISPR: Methods and Protocols (pp. xx-xx). New York, NY: Springer.

Makarova, K. S., et al. (2020). Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nature Reviews Microbiology, 18, 67–83.

Makarova, K. S., et al. (2015). An updated evolutionary classification of CRISPR–Cas systems. Nature Reviews Microbiology, 13, 722–736.

Mojica, F. J. M., Diez-Villasenor, C., Soria, E., & Juez, G. (2000). Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria, and mitochondria. Molecular Microbiology, 36(1), 244–246.

Mojica, F. J. M., Díez-Villaseñor, C., García-Martínez, J., & Soria, E. (2015). Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. Journal of Molecular Evolution, 60(2), 174–182.

Mojica, F. J. M., Juez, G., & Rodriguez-Valera, F. (2003). Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified PstI sites. Molecular Microbiology, 9(4), 613–621.

Mali, P., et al. (2013). RNA-guided human genome engineering via Cas9. Science, 339(6121), 823–826.

Makarova, K. S., et al. (2021). Evolution and classification of the CRISPR–Cas systems. Nature Reviews Microbiology, 9, 467–477.

Pourcel, C., Salvignol, G., & Vergnaud, G. (2015). CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology, 151(3), 653–663.

Stadtmauer, E. A., et al. (2020). CRISPR-engineered T cells in patients with refractory cancer. Science, 367, eaba7365.

Van Soolingen, D., De Haas, P. E. W., Hermans, P. W. M., Groenen, P. M. A., & Van Embden, J. D. A. (2013). Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of Mycobacterium tuberculosis. Journal of Clinical Microbiology, 31(8), 1987–1995.

Xu, L., et al. (2019). CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. New England Journal of Medicine, 381, 1240–1247.